202409-82-3

Usage

Structure

Pyridine derivative with a benzyl ether group and bromine and chlorine substituents

Usage

Intermediate in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds

Potential

Can be used in the development of new drugs and in research studies

Safety

Handle with care and follow proper safety protocols due to potential hazards

Upstream product

• 137628-16-1 3-bromo-5-chloro-2-hydroxypyridine 
• 100-39-0 benzyl bromide 
• 4214-79-3 5-chloro-2-pyridinol 
• 138006-41-4 3-bromo-2,5-dichloropyridine 
• 100-51-6 benzyl alcohol 

Downstream Products

• 690261-51-9 3-(2-bromo-phenyl)-5-chloro-2-(benzyloxy)-pyridine 
• 745050-28-6 2-benzoyloxy-5-chloro-3-[4-(methylthio)phenyl]pyridine 
• 442692-43-5 2-benzyloxy-5-chloro-3-(4-methoxyphenyl)-pyridine 
• 202409-84-5 2-Benzyloxy-5-chloro-3-(4-methylsulfonyl)phenylpyridine 

Relevant academic research and scientific papers

HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, isotopic form or prodrug thereof, wherein R1, L1,

8-OXY-QUINOLINE DERIVATIVES AS BRADYKININ B2 RECEPTOR MODULATORS

The present invention is related to compound of the formula (I): or a pharmacologically acceptable salt, solvate, or hydrate thereof, wherein A is a 6-membered heteroaryl having from 1 to 3 heteroatoms, each independently selected from N or O and the other substituents are defined as in the claims.

PHENYL COMPOUNDS

Compounds of formula (I) or derivatives thereof: wherein A, B, Z, R, R, R, R, R, and R are as defined in the specification, a process for the preparation of such compounds, pharmaceutical compositions comprising such compounds and the use of such compounds in medicine.

2,3'-BIPYRIDINES DERIVATIVES AS SELECTIVE COX-2 INHIBITORS

The present invention relates to 2,3'-bipyridines of formula (I). Processes for their preparation, pharmaceutical compositions containing them, and their medical uses.

Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease

The instant invention provides a drug combination comprised of an HMG-CoA reductase inhibitor in combination with a COX-2 inhibitor, which is useful for treating, preventing, and/or reducing the risk of developing atherosclerosis and atherosclerotic disease events.

Substituted pyridines as selective cyclooxygenase-2 inhibitors

The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.